Skip to Content
Merck
CN

Key Documents

View All Documentation

444283

MMP-13 Inhibitor

The MMP-13 Inhibitor, also referenced under CAS 544678-85-5, controls the biological activity of MMP-13. This small molecule/inhibitor is primarily used for Protease Inhibitors applications.

Synonym(s):

MMP-13 Inhibitor, Pyrimidine-4,6-dicarboxylic acid, bis-(4-fluoro-3-methyl-benzylamide)

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C22H20F2N4O2
CAS Number:
544678-85-5
Molecular Weight:
410.42
MDL number:
MFCD09878513
UNSPSC Code:
12352200
NACRES:
NA.77
Assay:
≥98% (HPLC)
Form:
solid
Quality level:
100
Storage condition:
OK to freeze, protect from light
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

100

assay

≥98% (HPLC)

form

solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze, protect from light

color

light yellow

solubility

DMSO: 10 mg/mL

shipped in

ambient

storage temp.

2-8°C

SMILES string

Fc1c(cc(cc1)CNC(=O)c2ncnc(c2)C(=O)NCc3cc(c(cc3)F)C)C

InChI

1S/C22H20F2N4O2/c1-13-7-15(3-5-17(13)23)10-25-21(29)19-9-20(28-12-27-19)22(30)26-11-16-4-6-18(24)14(2)8-16/h3-9,12H,10-11H2,1-2H3,(H,25,29)(H,26,30)

InChI key

PYFRREJCFXFNRR-UHFFFAOYSA-N

General description

A potent inhibitor of MMP-13 activity (IC50 = 8 nM) with expected selectivity over MMP-1, -2, -3, -7, -8, -9, -10, -12, -14 and -16 as determined by conformational structure analysis. Shown to bind to the MMP-13 catalytic domain and act as a non-zinc-chelating inhibitor.
A pyrimidine dicarboxamide compound that potently inhibits MMP-13 activity (IC50 = 8 nM) with expected selectivity over MMP-1, -2, -3, -7, -8, -9, -10, -12, -14 and -16 as determined by conformational structure analysis. Shown to bind to the MMP-13 catalytic domain and act as a non-zinc-chelating inhibitor.

Biochem/physiol Actions

Cell permeable: no
Primary Target
MMP-13 activity
Product does not compete with ATP.
Reversible: no
Target IC50: 8 nM against MMP-13

Packaging

Packaged under inert gas

Preparation Note

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Further dilute in buffer immediately prior to use.

Other Notes

Engel, C.K., et al. 2005. Chem. Biol.12, 181.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Standard Handling (A)

Storage Class

11 - Combustible Solids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Related Content

Protease Inhibitor Selection: Avoid Protein Loss in Sample Prep

Select different protease inhibitor types based on your needs to prevent protein degradation during isolation and characterization and safeguard proteins in sample prep.

Christian K Engel et al.
Chemistry & biology, 12(2), 181-189 (2005-03-01)
Inhibitors for matrix metalloproteinases (MMPs) are under investigation for the treatment of cancer, arthritis, and cardiovascular disease. Here, we report a class of highly selective MMP-13 inhibitors (pyrimidine dicarboxamides) that exhibit no detectable activity against other MMPs. The high-resolution X-ray
Spenser S Smith et al.
eLife, 11 (2022-06-07)
Precise developmental control of jaw length is critical for survival, but underlying molecular mechanisms remain poorly understood. The jaw skeleton arises from neural crest mesenchyme (NCM), and we previously demonstrated that these progenitor cells express more bone-resorbing enzymes including Matrix
Kristina Viiklepp et al.
The Journal of investigative dermatology (2021-11-11)
Cutaneous squamous cell carcinoma (cSCC) is the most common metastatic skin cancer with increasing incidence worldwide. Previous studies have demonstrated the role of complement system in cSCC progression. In this study we have investigated the mechanistic role of serine protease

Global Trade Item Number

SKUGTIN
444283-1MG04055977186000